Carl Landgren
University of Miami
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl Landgren as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:08 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05361694 · Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor ConditionsUniversity of Miami · recruiting · Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance · principal investigator
- Ph2NCT04268498 · A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaUniversity of Miami · active not recruiting · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Translational and Clinical Oncology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · fiscal years 2024 to 2026 · $32,537 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:08 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.Radiology · 202097 citationsRCR 4.9
- 91 citationsRCR 3.6
- Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.Biol Blood Marrow Transplant · 201839 citationsRCR 1.4
- Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.Biol Blood Marrow Transplant · 202013 citationsRCR 0.6
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.Leuk Lymphoma · 201811 citationsRCR 0.3